A metabolic drug improved movement scores in an early Parkinson's trial — by way of the mitochondria

A drug first developed for obesity and metabolic disease just posted a promising result in early Parkinson's — by way of the mitochondria. In a multicenter, double-blind, randomized, placebo-controlled Phase 2a trial, the metabolic agent vutiglabridin improved motor scores versus placebo over 24 weeks, with the higher dose producing a statistically significant 3.56-point advantage on the standard movement scale. The results were presented as a late-breaking abstract at the 2026 International Congress of Parkinson's Disease and Movement Disorders in Seoul.

The trial result — and the mitochondrial mechanism

The trial enrolled people with early-stage Parkinson's disease. Of 118 screened, 99 were randomized and 77 were included in the per-protocol efficacy analysis. The primary endpoint was change from baseline to week 24 in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III — the standard clinician-rated motor exam. Scores improved by 1.37 points in the 400 mg group and 2.83 points in the 800 mg group, while the placebo group worsened by 0.73 points — a mean difference of 3.56 points between the 800 mg dose and placebo (P=.03). The drug was reported as well tolerated, with no drug-related serious adverse events.

The mitochondria enter through the mechanism. Preclinical work published in Molecular Neurodegeneration showed vutiglabridin binds paraoxonase-2 (PON2), a mitochondrial enzyme; in MPTP-induced mouse models of Parkinson's, it reversed mitochondrial dysfunction, reduced oxidative stress, improved motor function, and protected dopaminergic neurons — effects that vanished in PON2-knockdown mice, tying the benefit to that target. The trial also measured serum PON1 activity as an exploratory biomarker, with the 800 mg group trending higher.

What it is and isn't

Phase 2a is a signal-seeking stage, and this is how it should be read: a real efficacy signal on the primary endpoint, in a properly controlled trial, for a drug whose animal mechanism runs directly through mitochondrial dysfunction. But the efficacy analysis was per-protocol rather than the full randomized set, the exploratory endpoints (striatal dopamine uptake by PET, neurofilament light chain) weren't numerically reported in the abstract, and nothing here yet says anything about slowing the disease itself.

If larger trials replicate the motor benefit and start filling in the biomarker picture, PON2 — a mitochondrial enzyme most people have never heard of — could become one of the more interesting new targets in Parkinson's. For now, it's a genuine lead with a plausible engine.

Where the evidence stands

• Established: The trial was multicenter, double-blind, randomized, and placebo-controlled; the 800 mg dose beat placebo on the MDS-UPDRS Part III primary endpoint (3.56-point difference, P=.03) with no drug-related serious adverse events.
• Preliminary: Vutiglabridin reversing mitochondrial dysfunction and protecting dopaminergic neurons via PON2 — shown in MPTP mouse models (Mol Neurodegener 2025); the human motor benefit is early-phase, per-protocol data needing larger confirmation.
• Absent: Any demonstrated effect on disease progression or long-term outcomes; Phase 2a is designed for efficacy signal and safety, not approval.